AUTHORS
Aimee Tran, MBBS, Diego Villa, MD2, Alina S. Gerrie, MD, FRCPC, MPH3, Graham Slack4, Christopher P. Venner, MD5, Andrew J. Cowan, MD6, Shannon Murphy, MD, MBA7, Amrit Kahlon, MD, FRCPC8, Roopesh Kansara, MD9, Aixiang Jiang, PhD10, David Scott, MD11, Laurie H. Sehn, MD12, Kerry Savage, MD, MSc, BSc13
AFFILIATIONS
1 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
2 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
3 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
4 BC Cancer, Vancouver, British Columbia, Canada, Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
5 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
6 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
7 Dalhousie University, Halifax, Nova Scotia, Canada
8 University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
9 University of Manitoba, Winnipeg, Manitoba, Canada
10 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
11 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
12 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
13 Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada, University of British Columbia, BC Cancer, Vancouver, British Columbia, Canada
ABSTRACT
Introduction: Rituximab (R) has been integral in the management of post-transplant lymphoproliferative disorders (PTLDs) with a sequential approach favored as supported by the PTLD-1 (Trappe et al 2012) and PTLD-2 (Zimmermann et al 2022) studies. In PTLD-2, following R monotherapy for all pts, those in complete remission (CR) or those with an IPI<3 and in PR, received 1 further R cycle and avoided chemotherapy (chemo), however, all pts with progression or those with an IPI 3-5 and not in CR switched to R-chemotherapy. We evaluated outcomes in PTLD occurring in solid organ transplant (SOT) pts, with a focus on monomorphic (mono)-DLBCL, evaluating long-term outcomes with a risk adapted strategy and the utility of the IPI in risk stratification.
Methods: The BC Cancer Lymphoid Cancer Database was screened to identify all pts ≥ 18 years (y) with PTLD following SOT from 2000-2025. Diagnoses were based on WHO classification used during era of diagnosis. Exclusions: T-cell lymphoma and low grade B cell lymphoma (BCL). In addition to reduction of immunosuppression (RIS), R monotherapy (weekly x 4) is the preferred initial therapy in BC for PTLD if feasible, with R-CHOP used for pts requiring a more immediate response and following PTLD-1, also for those in < CR after R. Time to progression (TTP) events=relapse/progression, death due to lymphoma/toxicity, and overall survival (OS) were evaluated. In mono DLBCL, a competing risk analysis to evaluate the 5y CI of relapse in pts who were event free at 24 months (EFS24) was performed.
Results: 235 pts were identified, 156(66.4%) were males; median age was 60 y (19-84). Transplant type: 151(64%) renal; 45(19%) liver; 23 (10%) lung; other 12(5%), pancreas/multi-organ 4(2%); 12 (5.1%) had a subsequent transplant (different organ n=5; same organ n=7). EBV+ tumor in 98 (41.5%). Median time from first transplant to PTLD was 9.9y (early PTLD <2y 22% vs late > 2y 78%).
The majority (207, 88%) had mono PTLD, most commonly DLBCL (182, 88%) with the remaining subtypes; plasmablastic lymphoma (10, 5%), Burkitt’s lymphoma/High-grade BCL (7, 3%), cHL (3, 1.4%), NOS (5, 2%); 28(22%) had polymorphic (poly) PTLD (27, 11.5%), or EBV+ mucocutaneous ulcer (EBV+mc) (1, 0.4%). 18 (7.7%) had central nervous system (CNS) involvement (isolated n=16). Most pts with poly PTLD received R alone (63%). For those with mono PTLD, 95% were planned for with curative intent therapy, including R-based therapy in 82%.
With a median follow up of 7.5y (95% CI 6.1-9.0), median OS was 7.74y, 5y OS 55.9%, 5 y DSS 59.3%, and 5y TTP 58%. TTP and DSS were inferior in mono vs poly/EBV+mc (TTP: 5/10y: 55.2%/47.8% vs 78.3%/78.3%, p=0.009; DSS: 5/10y 59.3%/56.1% vs 82.1% (for both), p=0.017) but OS was similar (5/10y OS: 53.7%/43.6% vs 72.6%/48.4%, p=0.17). Pts with mono PTLD post lung SOT had an inferior OS (5y: 24.1%, renal 56.6%, Liver 62%, other 40.9%) (p=0.03) and DSS (p=0.037), with more frequent early PTLD (p<0.001)
Considering only DLBCL without CNS involvement (n=170), the 5y TTP, DSS and OS were 55%, 59.5% and 53.1%, respectively. For pts who achieved EFS24 (n=86), the 5-year CI of relapse was 14.3%, and 5 y OS was 77.6%. Outcomes differed by IPI group: 5y TTP for 0/1 (n=30,18%), 79.2%; 2 (n=35, 21%) 66.5%; 3 (n=52, 32%)-61.9%; and 4/5 (n=46, 28%) 26.3% (p<0.001). TTP was improved in those initiated on R-chemo (n=84) (R-CHOP in 88%) compared to those on initiated on R alone (n=73) (5 y TTP 66.8% vs 46.5%, p=0.043) but DSS (p=0.486) and OS were similar (p= 0.37). In pts initially treated with R (n=73), 31(42%) received subsequent R-CHOP, 10 for partial remission (PR) on R (not a TTP event) and 24, had either progression on therapy or relapse following CR. Pts with IPI 0-2 had similar outcomes by treatment approach. However, for pts with IPI 3, TTP and OS were superior in those initiated on R-chemo vs R initial (5y TTP 73% vs 47%, p=<0.001; 5 y OS 76.7% vs 39.9%, p=0.023) with a trend for improved DSS with R-chemo (76.7% vs 50.7%, p=0.063). For those with IPI 4/5 outcomes were poor in both groups (5 y DSS 32.8% vs 13.7%, p=0.40). Finally, the survival following relapse/progression was poor with 5y OS of only 14.9%.
Conclusion: Outcomes of PTLD remain sub-optimal but for pts with DLBCL that reach EFS24, the 5y OS is favorable. Initial R monotherapy is appropriate for DLBCL with IPI 0-2, however, those with IPI 3 and higher may be better suited for initial R-chemotherapy and thus, careful selection is warranted.
DISCLOSURES
Aimee Tran, MBBS: No relevant conflicts of interest to declare.